Improving Healthcare Delivery: The FDA and CMS Policy Alignment for Cardiovascular Devices

By Staff Writer

November 2, 2023

Navigating the FDA and CMS Policy Alignment

Two of the most important pillars supporting the healthcare sector are the Food and Drug Administration (FDA) of the United States and the Centers for Medicare & Medicaid Services (CMS). The FDA is in charge of ensuring that medical devices are both safe and effective. The coverage and benefits that are provided to CMS’s beneficiaries are decided by CMS. Because of the different legislative authorities held by these two agencies, the regulatory environment that medical device manufacturers must operate in is quite complicated.

One such program run by the FDA is called the Breakthrough Devices Program, or BDP for short. Its purpose is to encourage innovation by bestowing Breakthrough designations early on in the process of device development in order to speed up the approval process for market release. This strategy is flexible enough to accommodate a higher degree of ambiguity regarding the benefits and risks involved, provided sufficient postmarket evidence is gathered.

 

The BDP’s Impact on Healthcare Costs and Innovation

The healthcare sector has been profoundly affected as a result of the BDP’s initiatives. Since the year 2020, devices that have been given the Breakthrough designation have, in effect, automatically qualified to receive supplementary Medicare reimbursement. This change came about as a result of CMS’s decision to relax a long-standing requirement that medical devices demonstrate “substantial clinical improvement” for the people they serve (the beneficiaries).

However, the BDP’s strategy has not been without of difficulties throughout its history. The BDP might make it possible for the FDA to grant approval based on evidence that isn’t quite as stringent, including single-arm trials that focus on surrogate end goals and only have short-term follow-up. Because of this strategy, several medical devices have been granted approval based on evidence that may not be typical of Medicare recipients as a whole.

There is a significant opportunity for the BDP to serve as a catalyst for innovation in the healthcare sector. On the other hand, this raises a number of issues in terms of ensuring that the highest quality evidence is provided to guide clinical care. In order to maintain this equilibrium, the FDA and CMS will need to continue to collaborate on the improvement of their respective rules and procedures.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.